CDK7 Inhibitor Dosing Regimens for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers, particularly those involving CDK7 overexpression or aberrant activity, lack specificity and efficacy, often leading to resistance and limited therapeutic options for patients with triple-negative breast cancer and other solid tumors.
Innovation Solution
Development of CDK7 inhibitors, specifically chemical compounds with a disclosed formula and their pharmaceutically acceptable salts, stereoisomers, and isotopic forms, which demonstrate selectivity for CDK7 over CDK2, CDK9, and CDK12, and are administered alone or in combination with other anti-cancer agents to target CDK7/cyclin H complexes, showing anti-proliferative activity and good bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CDK7 inhibitors are developed to target CDK7/cyclin H complexes, then selectivity and efficacy against CDK7 are improved, but off-target effects on other CDKs (CDK2, CDK9, CDK12) may occur
Solution Approach 1:
The patent applies local quality by designing CDK7 inhibitors with specific molecular structures (Formula I compounds) that target the unique ATP-binding pocket of CDK7. The inhibitors feature specific substituents (R1-R4 groups) that confer selectivity for the CDK7/cyclin H complex while minimizing interaction with other CDKs, thereby achieving high selectivity without broad off-target effects.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying chemical parameters of the CDK7 inhibitor molecules (such as the R1-R4 substituents in Formula I) to optimize binding affinity and selectivity for CDK7. By adjusting these molecular parameters, the inhibitors achieve high specificity for CDK7 while maintaining low activity against other CDK family members.
2Productivity
If CDK7 inhibitors are administered at high doses to achieve sufficient inhibition, then anti-proliferative activity is improved, but toxicity and safety issues arise
Solution Approach 1:
The patent applies parameter changes by optimizing the pharmacokinetic parameters of the CDK7 inhibitors through careful molecular design. The Formula I compounds are structured to achieve appropriate bioavailability, half-life, and concentration profiles that provide sufficient anti-proliferative activity at manageable doses, avoiding excessive toxicity while maintaining therapeutic efficacy.
3Ease of operation
If CDK7 inhibitors are used as monotherapy, then simplicity of treatment is improved, but resistance development occurs
Solution Approach 1:
The patent applies universality by designing CDK7 inhibitors that can function effectively both as monotherapy and in combination with other anti-cancer agents. The Formula I compounds are versatile enough to provide adequate anti-proliferative activity alone while also enhancing the efficacy of combination regimens, thereby maintaining treatment simplicity while preventing resistance through multi-functional use.
Solution Approach 2:
The patent utilizes dynamics by providing flexible dosing regimens that can be adjusted based on patient response and tumor characteristics. The intermittent dosing schedule (e.g., 1-4 days on treatment followed by 7-14 days off treatment) allows for dynamic adaptation to prevent resistance while maintaining treatment simplicity through a manageable cycling approach.
4Productivity
If continuous dosing is used to maintain inhibition, then therapeutic efficacy is improved, but patient compliance and safety are worsened
Solution Approach 1:
The patent applies periodic action by implementing intermittent dosing regimens where the CDK7 inhibitor is administered for a limited period (1-4 days) followed by a rest period (7-14 days). This periodic administration pattern maintains therapeutic efficacy through adequate drug exposure during treatment phases while significantly improving patient compliance and safety by allowing recovery periods, thereby reducing cumulative toxicity and improving quality of life.
Data Source
AI summary
The present invention provides for the use of various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, stereoisomers, and isotopic forms thereof in treating a proliferative disease such as cancer in a patient. Administration of a compound or pharmaceutical composition at a dose and conforming to a dosing regimen described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, treat the cancer.